Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference ivps42019-06-20T12:11:56-05:00 Read More
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial ivps42019-06-10T19:47:43-05:00 Read More
Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline ivps42019-05-29T12:26:30-05:00 Read More
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update ivps42019-05-15T15:43:49-05:00 Read More
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019 ivps42019-04-30T18:19:42-05:00 Read More
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation ivps42019-04-23T15:51:25-05:00 Read More
Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019 ivps42019-03-28T13:05:13-05:00 Read More
Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation ivps42019-03-29T12:54:22-05:00 Read More
Achieve Life Sciences to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 ivps42019-03-15T13:39:47-05:00 Read More
